小児急性熱性皮膚粘膜リンパ節症候群(MCLS):世界の治験レビュー(2017年下半期版)

◆英語タイトル:Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Global Clinical Trials Review, H2, 2017
◆商品コード:GDHC4686CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:58
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における小児急性熱性皮膚粘膜リンパ節症候群(MCLS)治療の臨床試験動向について調査・分析し、アジア/ヨーロッパ/アメリカ/中南米の主要国における治験件数、フェーズ別の治験件数、進捗状況別の治験件数、有望なスポンサー、有望な薬剤、治験関連の最新ニュース、主要企業分析、主要な治験プロファイル分析などの情報をご提供致します。
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):主要地域別治験動向
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):アジア市場
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):ヨーロッパ市場
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):アメリカ市場
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):中南米市場
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):中東・アフリカ市場
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):段階(フェーズ)別治験件数
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):進捗状況別の治験件数
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):スポンサーの種類別治験件数
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):有望なスポンサー
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):有望な薬剤分析
・小児急性熱性皮膚粘膜リンパ節症候群(MCLS):主要企業分析
【レポートの概要】

Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Global Clinical Trials Review, H2, 2017

Summary

GlobalData’s clinical trial report, “Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Global Clinical Trials Review, H2, 2017″ provides an overview of Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Mucocutaneous Lymph Node Syndrome (Kawasaki Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) to Immunology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) to Immunology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials 27
Prominent Drugs 28
Clinical Trial Profile Snapshots 29
Appendix 56
Abbreviations 56
Definitions 56
Research Methodology 57
Secondary Research 57
About GlobalData 58
Contact Us 58
Source 58

List of Tables
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials by Region, 2017* 7
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 10
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 13
Proportion of Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) to Immunology Clinical Trials, G7 Countries (%), 2017* 14
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
Proportion of Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) to Immunology Clinical Trials, E7 Countries (%), 2017* 17
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 19
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials by Phase, 2017* 20
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 21
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 25
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28

List of Figures
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 10
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
Proportion of Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) to Immunology Clinical Trials, G7 Countries (%), 2017* 14
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
Proportion of Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) to Immunology Clinical Trials, E7 Countries (%), 2017* 17
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 19
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 20
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 21
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 25
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28
GlobalData Methodology 57

【掲載企業】

Mitsubishi Chemical Holdings Corp
Johnson & Johnson
Inpads GmbH
Green Cross Holdings Corp
CSL Ltd
Creat Group Corp
China Biologic Products Inc
Celixir Ltd
Bristol-Myers Squibb Co
Amgen Inc

【レポートのキーワード】

小児急性熱性皮膚粘膜リンパ節症候群(MCLS)、治験、臨床試験、治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 小児急性熱性皮膚粘膜リンパ節症候群(MCLS):世界の治験レビュー(2017年下半期版)(Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Global Clinical Trials Review, H2, 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆